MedDataX Logo

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

NCT ID: NCT02242331

Last Updated: 2014-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19805 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the control of blood pressure in the morning before intake of the next antihypertensive drug

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

NCT02176850

Hypertension
COMPLETED

Micardis®. Observational Study in Patients With Essential Hypertension

NCT02200094

Hypertension
COMPLETED

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

NCT02238262

Hypertension
COMPLETED

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

NCT02242318

Hypertension
COMPLETED PHASE4

Pharmacovigilance and Patient Compliance in Hypertensive Patients

NCT02200575

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

essential hypertension patients

Micardis®

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micardis®

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Essential hypertension
* At least 18 years of age

Exclusion Criteria

* NA
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.386

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
NCT00034840 COMPLETED PHASE4
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
NCT00240448 COMPLETED PHASE4
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
NCT02177396 COMPLETED PHASE3
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710 COMPLETED PHASE3
Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
NCT02242851 COMPLETED
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT00471003 COMPLETED
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension
NCT00759551 COMPLETED PHASE2
A Single Rising Dose Study of MK-8150 (MK-8150-001)
NCT01590810 COMPLETED PHASE1
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
NCT00168779 COMPLETED PHASE4
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 COMPLETED PHASE3
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
NCT00996281 COMPLETED PHASE3
A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension
NCT03276598 COMPLETED PHASE4
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00696241 COMPLETED PHASE3
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
NCT00422461 COMPLETED PHASE2
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
NCT05843162 UNKNOWN PHASE4
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
NCT00241007 COMPLETED PHASE3
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00696384 COMPLETED PHASE3
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00695955 COMPLETED PHASE3
Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)
NCT01025843 COMPLETED PHASE1
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
NCT02515331 COMPLETED PHASE2
Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study
NCT04030234 COMPLETED NA
Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data
NCT04354376 COMPLETED
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
NCT00696436 COMPLETED PHASE3
Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
NCT01928628 COMPLETED PHASE3
Antihypertensive Medications and the Risk of Sepsis
NCT02248896 COMPLETED